# A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

> **NCT00398788** · PHASE2 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 207 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine

## Key facts

- **NCT ID:** NCT00398788
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2001-11
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398788, "A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00398788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*